Nasamet (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal mucosa. This binding alters gene expression, decreasing the release of inflammatory mediators such as cytokines and chemokines, which reduces swelling, mucus production and irritation in the nose.

The specific dose and frequency of Nasamet are determined by the prescribing clinician based on the patient’s age, severity of symptoms and treatment response. Patients should follow the prescriber’s instructions and the product labeling for proper use.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made together with a healthcare professional.

To order Nasamet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nasamet (mometasone furoate) and fluticasone are both potent nasal corticosteroids with similar anti‑inflammatory actions. Mometasone furoate has a high receptor affinity and a once‑daily dosing schedule for many patients, while fluticasone may be dosed once or twice daily depending on the formulation.

Nasamet should be stored at room temperature, below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Nasamet is administered as a nasal spray. The patient should gently blow the nose, insert the nozzle into one nostril, close the opposite nostril with a finger, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, although rare, include nasal septal perforation, secondary infections such as fungal sinusitis, and systemic effects like adrenal suppression. Patients should report persistent nosebleeds, unusual nasal pain, visual changes or signs of infection to their healthcare provider promptly.

Nasamet should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. Patients with active untreated bacterial, fungal or viral infections of the nasal passages, or those who have recently undergone nasal surgery, should consult a physician before use.